

Bruce A Mungall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5636632/publications.pdf>

Version: 2024-02-01

36
papers

2,334
citations

201674
27
h-index

345221
36
g-index

36
all docs

36
docs citations

36
times ranked

2363
citing authors

#	ARTICLE	IF	CITATIONS
1	A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. <i>Expert Review of Vaccines</i> , 2022, 21, 201-214.	4.4	17
2	A systematic review of the burden of pertussis in South Korea. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1747-1756.	3.3	8
3	Ten years of experience with the pneumococcal non-typeable <i>Haemophilus influenzae</i> protein D-conjugate vaccine (Synflorix) in children. <i>Expert Review of Vaccines</i> , 2020, 19, 247-265.	4.4	16
4	A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable <i>Haemophilus influenzae</i> Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 331-345.	2.1	6
5	Literature review of the epidemiology of influenza B disease in 15 countries in the Asia-Pacific region. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 383-411.	3.4	50
6	Letter to the editor to: Isturiz et al. <i>Streptococcus pneumoniae</i> serotype 19A: worldwide epidemiology. <i>Expert review of vaccines</i> 2017;16(10):1007-27. <i>Expert Review of Vaccines</i> , 2018, 17, 665-668.	4.4	1
7	Response to Wu et al. "Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2675-2680.	3.3	5
8	Anti-hepatitis B activity of isoquinoline alkaloids of plant origin. <i>Archives of Virology</i> , 2014, 159, 1119-1128.	2.1	26
9	Lectin-Dependent Enhancement of Ebola Virus Infection via Soluble and Transmembrane C-type Lectin Receptors. <i>PLoS ONE</i> , 2013, 8, e60838.	2.5	67
10	Characterization of the antiviral and inflammatory responses against Nipah virus in endothelial cells and neurons. <i>Virology</i> , 2010, 404, 78-88.	2.4	69
11	A Novel L-ficolin/Mannose-binding Lectin Chimeric Molecule with Enhanced Activity against Ebola Virus. <i>Journal of Biological Chemistry</i> , 2010, 285, 24729-24739.	3.4	51
12	Viral Entry Inhibitors Targeted to the Membrane Site of Action. <i>Journal of Virology</i> , 2010, 84, 6760-6768.	3.4	89
13	Journal of Antivirals & Antiretrovirals. <i>Journal of Antivirals & Antiretrovirals</i> , 2010, 2, 1-10.	0.1	19
14	Determination of the henipavirus phosphoprotein gene mRNA editing frequencies and detection of the C, V and W proteins of Nipah virus in virus-infected cells. <i>Journal of General Virology</i> , 2009, 90, 398-404.	2.9	67
15	Simulating Henipavirus Multicycle Replication in a Screening Assay Leads to Identification of a Promising Candidate for Therapy. <i>Journal of Virology</i> , 2009, 83, 5148-5155.	3.4	80
16	Human Parainfluenza Virus Infection of the Airway Epithelium: Viral Hemagglutinin-Neuraminidase Regulates Fusion Protein Activation and Modulates Infectivity. <i>Journal of Virology</i> , 2009, 83, 6900-6908.	3.4	64
17	Kinetic Dependence of Paramyxovirus Entry Inhibition. <i>Journal of Virology</i> , 2009, 83, 6947-6951.	3.4	29
18	Characteristics of Nipah virus and Hendra virus replication in different cell lines and their suitability for antiviral screening. <i>Virus Research</i> , 2009, 142, 92-99.	2.2	38

#	ARTICLE	IF	CITATIONS
19	Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro. <i>Virology Journal</i> , 2009, 6, 187.	3.4	41
20	Inhibition of Henipavirus infection by RNA interference. <i>Antiviral Research</i> , 2008, 80, 324-331.	4.1	35
21	Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus. <i>Journal of Virological Methods</i> , 2008, 149, 12-19.	2.1	39
22	Henipavirus susceptibility to environmental variables. <i>Virus Research</i> , 2008, 132, 140-144.	2.2	112
23	Tioman Virus, a Paramyxovirus of Bat Origin, Causes Mild Disease in Pigs and Has a Predilection for Lymphoid Tissues. <i>Journal of Virology</i> , 2008, 82, 565-568.	3.4	42
24	Vertical Transmission and Fetal Replication of Nipah Virus in an Experimentally Infected Cat. <i>Journal of Infectious Diseases</i> , 2007, 196, 812-816.	4.0	46
25	Recent progress in henipavirus research. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2007, 30, 287-307.	1.6	40
26	Feline Model of Acute Nipah Virus Infection and Protection with a Soluble Glycoprotein-Based Subunit Vaccine. <i>Journal of Virology</i> , 2006, 80, 12293-12302.	3.4	166
27	Potent Neutralization of Hendra and Nipah Viruses by Human Monoclonal Antibodies. <i>Journal of Virology</i> , 2006, 80, 891-899.	3.4	155
28	Receptor Binding, Fusion Inhibition, and Induction of Cross-Reactive Neutralizing Antibodies by a Soluble G Glycoprotein of Hendra Virus. <i>Journal of Virology</i> , 2005, 79, 6690-6702.	3.4	157
29	From The Cover: Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 10652-10657.	7.1	395
30	Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein. <i>Virology Journal</i> , 2005, 2, 57.	3.4	71
31	Reassortment and evolution of current human influenza A and B viruses. <i>Virus Research</i> , 2004, 103, 55-60.	2.2	72
32	Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. <i>Virus Research</i> , 2004, 103, 195-197.	2.2	48
33	Intercontinental Circulation of Human Influenza A(H1N2) Reassortant Viruses during the 2001-2002 Influenza Season. <i>Journal of Infectious Diseases</i> , 2002, 186, 1490-1493.	4.0	58
34	In situ zymography: topographical considerations. <i>Journal of Proteomics</i> , 2001, 47, 169-176.	2.4	16
35	In vitro evidence for a bacterial pathogenesis of equine laminitis. <i>Veterinary Microbiology</i> , 2001, 79, 209-223.	1.9	92
36	Zymographic analysis of equine laminitis. <i>Histochemistry and Cell Biology</i> , 1999, 112, 0467-0472.	1.7	47